enGene (NASDAQ:ENGN) Coverage Initiated by Analysts at Guggenheim

Guggenheim started coverage on shares of enGene (NASDAQ:ENGN) in a report issued on Monday morning, MarketBeat reports. The firm issued a buy rating and a $34.00 price objective on the stock.

A number of other research firms also recently commented on ENGN. UBS Group initiated coverage on shares of enGene in a report on Thursday, March 28th. They set a buy rating and a $37.00 price objective on the stock. Leerink Partnrs reissued an outperform rating on shares of enGene in a report on Tuesday, February 20th. SVB Leerink began coverage on shares of enGene in a report on Tuesday, February 20th. They set an outperform rating and a $31.00 price objective on the stock. Finally, Morgan Stanley began coverage on shares of enGene in a report on Friday, March 8th. They issued an overweight rating and a $40.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and an average target price of $35.50.

enGene Trading Down 10.0 %

ENGN stock opened at $14.17 on Monday. enGene has a 52 week low of $6.69 and a 52 week high of $43.00. The business’s 50-day moving average is $15.83.

Institutional Trading of enGene

Several institutional investors and hedge funds have recently modified their holdings of ENGN. Citadel Advisors LLC purchased a new stake in shares of enGene in the fourth quarter valued at about $185,000. Goldman Sachs Group Inc. purchased a new position in shares of enGene during the fourth quarter valued at approximately $346,000. Royal Bank of Canada purchased a new position in shares of enGene during the fourth quarter valued at approximately $349,000. Vivo Capital LLC purchased a new position in shares of enGene during the fourth quarter valued at approximately $6,264,000. Finally, Omega Fund Management LLC purchased a new position in shares of enGene during the fourth quarter valued at approximately $10,441,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.